Amgen IncNASDAQ:AMGN
- LAST PRICE315.1500
- TODAY'S CHANGE (%)-4.1600 (-1.3028%)
- Bid / Lots315.0000/ 2
- Ask / Lots315.1800/ 1
- Open / Previous Close317.1800 / 319.3100
- Day Range
- 52 Week Range
- Volume738,988
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMGN |
|---|---|---|
| 09:32 ET | 49098 | 315.99 |
| 09:34 ET | 2134 | 316.625 |
| 09:36 ET | 10688 | 316.625 |
| 09:38 ET | 1308 | 316.3027 |
| 09:39 ET | 10226 | 316.975 |
| 09:41 ET | 3764 | 316.95 |
| 09:43 ET | 8226 | 315.62 |
| 09:45 ET | 6080 | 314.44 |
| 09:48 ET | 11631 | 315.2 |
| 09:50 ET | 6063 | 315.3477 |
| 09:52 ET | 4179 | 316.295 |
| 09:54 ET | 3353 | 315.545 |
| 09:56 ET | 600 | 315.3 |
| 09:57 ET | 2402 | 315.22 |
| 09:59 ET | 3400 | 315.88 |
| 10:01 ET | 14583 | 315.51 |
| 10:03 ET | 3873 | 315.765 |
| 10:06 ET | 3346 | 315.795 |
| 10:08 ET | 3848 | 316 |
| 10:10 ET | 1403 | 316.095 |
| 10:12 ET | 4440 | 315.375 |
| 10:14 ET | 9694 | 315.325 |
| 10:15 ET | 2713 | 315.65 |
| 10:17 ET | 1063 | 315.695 |
| 10:19 ET | 9678 | 315.61 |
| 10:21 ET | 4641 | 315.735 |
| 10:24 ET | 5598 | 316.27 |
| 10:26 ET | 2005 | 316.245 |
| 10:28 ET | 5871 | 316.3 |
| 10:30 ET | 8007 | 316.165 |
| 10:32 ET | 12647 | 316.315 |
| 10:33 ET | 19802 | 316.35 |
| 10:35 ET | 3620 | 316.565 |
| 10:37 ET | 4800 | 316.75 |
| 10:39 ET | 15579 | 316.8 |
| 10:42 ET | 14739 | 316.665 |
| 10:44 ET | 14656 | 316.0755 |
| 10:46 ET | 3006 | 316.75 |
| 10:48 ET | 900 | 316.28 |
| 10:50 ET | 3377 | 315.9101 |
| 10:51 ET | 2394 | 316.165 |
| 10:53 ET | 3297 | 315.915 |
| 10:55 ET | 5659 | 316.05 |
| 10:57 ET | 1870 | 316.005 |
| 11:00 ET | 2711 | 315.95 |
| 11:02 ET | 3913 | 316.1 |
| 11:04 ET | 5680 | 315.43 |
| 11:06 ET | 3438 | 314.8362 |
| 11:08 ET | 7426 | 314.73 |
| 11:09 ET | 2700 | 315.02 |
| 11:11 ET | 1300 | 314.84 |
| 11:13 ET | 3769 | 314.5983 |
| 11:15 ET | 2554 | 314.4201 |
| 11:18 ET | 9040 | 315.5 |
| 11:20 ET | 3826 | 315.935 |
| 11:22 ET | 7990 | 315.67 |
| 11:24 ET | 2614 | 315.38 |
| 11:26 ET | 1225 | 315.48 |
| 11:27 ET | 4418 | 315.6725 |
| 11:29 ET | 1479 | 315.51 |
| 11:31 ET | 3793 | 315.26 |
| 11:33 ET | 5392 | 315.12 |
| 11:36 ET | 6795 | 315.15 |
| 11:38 ET | 1898 | 314.77 |
| 11:40 ET | 4934 | 314.955 |
| 11:42 ET | 1100 | 314.99 |
| 11:44 ET | 7251 | 315.15 |
| 11:45 ET | 11116 | 315.065 |
| 11:47 ET | 800 | 314.94 |
| 11:49 ET | 2714 | 315.15 |
Yesterday
DJ Amgen on Track for Record High Close -- Data Talk, from 10:20AM ET on Tuesday Jun 25, 2024 by Dow Jones
10:20AM ET on Tuesday Jun 25, 2024 by Dow Jones
Jun 20, 2024
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033, from 8:45AM ET on Thursday Jun 20, 2024 by Dow Jones
8:45AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 19, 2024
DJ M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com, from 1:30AM ET on Wednesday Jun 19, 2024 by Dow Jones
1:30AM ET on Wednesday Jun 19, 2024 by Dow Jones
Jun 14, 2024
DJ Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto, from 4:43PM ET on Friday Jun 14, 2024 by Dow Jones
4:43PM ET on Friday Jun 14, 2024 by Dow JonesFDA APPROVES BLINCYTO(R) (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE, from 4:21PM ET on Friday Jun 14, 2024 by Dow Jones
4:21PM ET on Friday Jun 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amgen Inc | 171.3B | 45.0x | -0.22% |
Gilead Sciences Inc | 86.7B | 193.5x | +1.53% |
Novartis AG | 235.2B | 24.2x | -5.59% |
AstraZeneca PLC | 246.7B | 39.2x | +17.52% |
Haleon PLC | 38.5B | 28.7x | --- |
Bristol-Myers Squibb Co | 85.5B | -13.7x | +4.90% |
Company Information
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Contact Information
- Headquarters
- One Amgen Center DriveTHOUSAND OAKS, CA, United States 91320
- Phone
- 805-447-1000
- Fax
- 805-447-1010
Executives
- Chairman of the Board, President, Chief Executive Officer
- Robert Bradway
- Chief Financial Officer, Executive Vice President
- Peter Griffith
- Executive Vice President, Chief Technology Officer
- David Reese
- Executive Vice President, Research and Development, and Chief Scientific Officer
- James Bradner
- Executive Vice President, General Counsel, Secretary
- Jonathan Graham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $171.3B |
|---|---|
Revenue (TTM) | $29.5B |
Shares Outstanding | 536.4M |
Dividend Yield | 2.86% |
Annual Dividend Rate | 9.0000 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-07-24 |
Beta | 0.58 |
EPS | $7.00 |
Book Value | $11.64 |
P/E Ratio | 45.0x |
Price/Sales (TTM) | 5.8 |
Price/Cash Flow (TTM) | 20.6x |
Operating Margin | 24.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
